



December 19, 2011

Re: Update Regarding Supply of Cerezyme® (imiglucerase for injection)

Dear Gaucher Community,

We would like to provide an update regarding our expectations for supply of Cerezyme.

We expect to provide the following for patients in the U.S.:

- Patients 19 years of age and older currently treated with Cerezyme:
 - In January and February: One dose (equivalent to the currently prescribed dose) per month
 - In March: Two doses (each equivalent to the currently prescribed dose)
- Patients 18 years of age and younger and Type 2/3 patients currently treated with Cerezyme will continue to receive two doses (each equivalent to the currently prescribed dose) per month.

As a reminder, most patients normally receive Cerezyme infusions at one prescribed dose every two weeks. For patients on alternate dosing schedules, your Case Manager will be able to provide detailed supply information. Genzyme will confirm shipping availability each month; note that the timing of shipping availability may vary somewhat month to month. We continue to make Cerezyme available to patients as it is produced to meet patient demand. Since we therefore have minimal inventory, any change to our manufacturing plans can have an immediate impact on our ability to provide product. Your doctor was notified of the above mentioned supply notification. Please speak with your doctor about managing your care.

Because of Cerezyme supply constraints, and the availability of alternative therapies, Genzyme cannot accommodate patients naïve to treatment, patients switching therapies or restart patients who were previously on Cerezyme. We are also unable to accept additional patients onto our charitable access programs.

Our overall supply outlook for Cerezyme continues to improve, and we believe it will continue to do so through 2012. Our current productivity and progress with our manufacturing recovery remains on track, and we will update the community again in March.

We sincerely regret the disruption to your treatment plans. We remain committed to providing supply updates as new information develops and will work closely with you to minimize the impact of any supply disruption. For any questions, please contact your local Genzyme Representative, or Case Manager at 1-800-745-4447, Option 3, or Genzyme Medical Information at 1-800-745-4447, Option 2.

Sincerely,

Jamie Petkunas, Associate Director
Genzyme Care Coordination

Stephanie Okey, M.S.
Vice President & General Manager, US PGH

Please see accompanying full Prescribing Information

CZ-US-P410-12-11